Denali Therapeutics Inc. Common Stock (DNLI) Financials

Key financial figures for Denali Therapeutics Inc. Common Stock (Q2 2026).

Denali Therapeutics reported revenue of $3.6 million for Q2 FY2026. The company posted a net loss of $127.6 million, or -$0.68 per share. Operating margin came to -3622.11%. Free cash flow for the period was -$97.8 million. The figures above are as filed, and the full income statement, balance sheet and cash flow history for Denali Therapeutics are on the SentiSense financials page.

Revenue
$4M
Net Income
-$128M
EPS
$-0.68
Total Assets
$1.2B
Operating Cash Flow
-$97M

Recent quarters

PeriodRevenueNet IncomeEPSOperating MarginFree Cash Flow
Q2 FY2026$4M-$128M-$0.68-3622.11%-$98M
Q1 FY2026$0-$128M-$0.69-$134M
Q4 FY2025$0-$129M-$0.73-$100M
Q3 FY2025$0-$127M-$0.74
Q2 FY2025$0-$124M-$0.72-$80M

Recent fiscal years

PeriodRevenueNet IncomeEPSOperating MarginFree Cash Flow
FY2025$0-$513M-$2.97-$422M
FY2024$0-$423M-$2.57-$364M
FY2023$331M-$145M-$1.06-59.51%-$371M

Frequently asked questions

What was Denali Therapeutics's revenue last quarter?

Denali Therapeutics reported revenue of $3.6 million for Q2 FY2026.

Is Denali Therapeutics profitable?

Not in its most recent reported period. Denali Therapeutics reported a net loss of $127.6 million for Q2 FY2026, a net margin of -3539.21% on revenue.

How has Denali Therapeutics's margin trended?

Operating margin was -3622.11% in Q2 FY2026. The quarter by quarter series is on the SentiSense financials page.

How much free cash flow did Denali Therapeutics generate?

Denali Therapeutics generated free cash flow of -$97.8 million in Q2 FY2026, after capital expenditure.

Full income statement, balance sheet and cash flow for Denali Therapeutics Inc. Common Stock on SentiSense, with up to forty quarters and twenty fiscal years of history.